Latigo Biotherapeutics, Inc. (LTGO) stock
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
Latigo Biotherapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Latigo Biotherapeutics's enterprise value was -$41.64M on Nov 11, 2026.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$41.64M | – |
See a number that looks wrong?